Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PLEC | Q15149 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GALK1 | P51570 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22260024 | 0.91 | PTGES (1.00) | PTGESMEN1KMT2ADNMT1BLM | |
| SCHEMBL1900374 | 0.82 | KMT2A (0.80) | PTGESMEN1KMT2ADNMT1BLM | |
| SCHEMBL1900377 | 0.82 | KMT2A (0.80) | PTGESMEN1KMT2ADNMT1BLM | |
| SCHEMBL1900378 | 0.82 | KMT2A (0.80) | PTGESMEN1KMT2ADNMT1BLM | |
| SCHEMBL27440675 | 0.80 | PTGES (0.66) | PTGESMEN1KMT2ADNMT1PTPN1 | |
| SCHEMBL22260032 | 0.79 | PTGES (1.00) | PTGES | |
| SCHEMBL22259725 | 0.78 | PTGES (1.00) | PTGES | |
| SCHEMBL22260022 | 0.76 | PTGES (0.69) | PTGESMEN1KMT2A | |
| SCHEMBL15817056 | 0.75 | CA9 (0.78) | PTPN1MAPK1 | |
| SCHEMBL15817052 | 0.75 | CA9 (0.78) | PTPN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030877-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030877-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-11325901-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-11220497-B2 | — | — | 2022-01-11 | — | — | US | disclosed |
| US-20200231583-A1 | Prostaglandin E Synthase Inhibitors and Methods for Utilizing the Same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325901-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | PTGES, PTGS1, PTGES2 | PTGES 1/4885MEN1 4764/4885KMT2A 4205/4885 |
| US-11220497-B2 | — | PTGES, PTGS1, PTGES2 | PTGES 1/4885MEN1 4668/4885KMT2A 4322/4885 |
| US-20200231583-A1 | Prostaglandin E Synthase Inhibitors and Methods for Utilizing the Same | PTGES, PTGS1, PTGES2 | PTGES 1/4885MEN1 4764/4885KMT2A 4205/4885 |
| US-12030877-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | PTGES, PTGS1, PTGES2 | PTGES 1/4885MEN1 4764/4885KMT2A 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.